ScreenerHero

AVCT Avacta Group Plc

LSE · GB · Healthcare · Biotechnology · avacta.com
72.00GBp0.00%Mkt Cap: 357.62M $P/E: —

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug co…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap357.62M USD
Enterprise Value366.36M USD
Revenue (TTM)122.83K USD
Gross Profit122.83K USD
Net Income (TTM)-41.97M USD
Revenue/Share0.00 GBp
Last Price72.00 GBp
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees81
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.72
PEG—
EV/EBITDA-11.27
EV/Revenue2982.79
P/S2911.61
P/B90.00
EPS (TTM)-0.09
EPS (Forward)-0.05
52W Range
0.000078% of range92.00
52W High92.00 GBp
52W Low0.0000 GBp
Profitability
Gross Margin100.00%
Oper. Margin-24419.64%
EBITDA Margin0.00%
Profit Margin-34169.91%
ROE-1559.45%
ROA-131.26%
Growth
Revenue Growth0.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.11M USD
CapEx (TTM)57.61K USD
FCF Margin-15198.45%
FCF Yield-5.22%
Net Debt-444.57K USD
Net Debt/EBITDA0.01
Balance Sheet
Debt/Equity6.02
Current Ratio0.95
Quick Ratio0.95
Book Value/Sh0.0080 GBp
Cash/Share0.04 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 GBp
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateJan 26, 2016
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)94.25 GBp
Upside (mean)+30.9%
Target Range60.00 GBp – 122.00 GBp
60.00+30.9% to mean122.00
# Analysts4
Ownership
Shares Out.437.63M
Float440.86M
Insiders3.08%
Institutions3.23%
Technical
SMA 5069.74 (+3.2%)
SMA 20068.35 (+5.3%)
Beta-0.11
S&P 52W Chg14.58%
Avg Vol (30d)1.41M
Avg Vol (10d)637.10K
Technical Indicators
RSI (14)49.0
MACD0.8218
MACD Signal1.3744
MACD Hist.-0.5527
BB Upper81.32 GBp
BB Middle73.12 GBp
BB Lower64.92 GBp
BB Width22.42%
ATR (14)3.764 GBp
Vol Ratio (20d)0.00x